The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2× · see citing works

Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults

Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482 · see citing works

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · see citing works

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · see citing works

Obesity: global epidemiology and pathogenesis

Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126 · see citing works

2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763 · see citing works

2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults

Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058 · see citing works

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Zhou, B., Carrillo-Larco, R. M., Danaei, G., Riley, L. M., Paciorek, C. J., Stevens, G. A., Gregg, E. W., Bennett, J. E., Solomon, B., Singleton, R. K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01330-1 · Cited by 3,902 · see citing works

The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · see citing works

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · see citing works

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · see citing works

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works

The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems.

(2015) · PubMed Central · Cited by 2,540 · see citing works

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · see citing works

The Metabolic Syndrome: Time for a Critical Appraisal

Kahn, R., Buse, J. B., Ferrannini, E., & Stern, M. P. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,377 · see citing works

Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · see citing works

Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial

Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 1× · see citing works

Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus

Wilson, P. W. F., D’Agostino, R. B., Parise, H., SULLIVAN, L. M., & Meigs, J. B. (2005) · Circulation · doi:10.1161/circulationaha.105.539528 · Cited by 2,061 · see citing works

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997 · see citing works

American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity

Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · see citing works

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial

Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829 · see citing works

A Randomized Trial of a Low-Carbohydrate Diet for Obesity

Foster, G. D., Wyatt, H. R., Hill, J. O., McGuckin, B. G., Brill, C., Mohammed, B. S., Szapary, P. O., Rader, D. J., Edman, J. S., & Klein, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022207 · Cited by 1,794 · see citing works

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 2× · see citing works

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 2× · see citing works

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art

Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · see citing works

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 1× · see citing works

Obesity-Induced Hypertension: Interaction of Neurohumoral and Renal Mechanisms

Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2015) · Circulation Research · doi:10.1161/circresaha.116.305697 · Cited by 1,360 · see citing works

Effect of weight loss with lifestyle intervention on risk of diabetes

Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delahanty, L., Hoskin, M., Kriska, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0560 · Cited by 1,344 · see citing works

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 3× · see citing works

The mechanism of pancreatic secretion

Bayliss, W. M., & Starling, E. H. (1902) · The Journal of Physiology · doi:10.1113/jphysiol.1902.sp000920 · Cited by 1,274 · see citing works

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial

Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · see citing works

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1× · see citing works

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048 · see citing works

The Public Health Impact of Obesity

Visscher, T. L. S., & Seidell, J. C. (2001) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.22.1.355 · Cited by 1,013 · see citing works

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · see citing works

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

Deacon, C. F., Nauck, M. A., Toft-Nielsen, M.-B., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diabetes.44.9.1126 · Cited by 878 · see citing works

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850 · see citing works

Semaglutide lowers body weight in rodents via distributed neural pathways.

Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · see citing works

Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693 · see citing works

2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea

Seo, M. H., Lee, W., Kim, S. S., Kang, J., Kang, J., Kim, K. K., Kim, B.-Y., Kim, Y., Kim, W., Kim, E. M., et al. (2019) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2019.28.1.40 · Cited by 680 · see citing works

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation

Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · see citing works

Exon duplication and divergence in the human preproglucagon gene

Bell, G. I., Sanchez-Pescador, R., Laybourn, P. J., & Najarian, R. C. (1983) · Nature · doi:10.1038/304368a0 · Cited by 593 · see citing works

Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action

Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577 · see citing works

Untitled work

Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560 · see citing works

Transcellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist

Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7047 · Cited by 553 · see citing works

Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of <i>The Obesity Society</i> and the <i>American Society of Hypertension</i>

Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D., & Sowers, J. (2013) · The Journal of Clinical Hypertension · doi:10.1111/jch.12049 · Cited by 528 · see citing works

GLP-1 receptor activation and epac2 link atrial natriuretic peptide secretion to control of blood pressure

Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514 · see citing works

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways

Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509 · see citing works

Pancreatic safety of incretin-based drugs–FDA and EMA assessment

Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498 · see citing works

Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men

Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442 · see citing works

Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials

Ge, L., Sadeghirad, B., Ball, G. D. C., da Costa, B. R., Hitchcock, C. L., Svendrovski, A., Kiflen, R., Quadri, K., Kwon, H. Y., Karamouzian, M., et al. (2020) · BMJ · doi:10.1136/bmj.m696 · Cited by 426 · see citing works

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407 · see citing works

Direct medical costs of obesity in the United States and the most populous states

Cawley, J., Biener, A., Meyerhoefer, C., Ding, Y., Zvenyach, T., Smolarz, B. G., & Ramasamy, A. (2021) · Journal of Managed Care &amp; Specialty Pharmacy · doi:10.18553/jmcp.2021.20410 · Cited by 400 · see citing works

Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery

Shariq, O. A., & McKenzie, T. J. (2020) · Gland Surgery · doi:10.21037/gs.2019.12.03 · Cited by 396 · see citing works

Effect of exercise training on weight loss, body composition changes, and weight maintenance in adults with overweight or obesity: An overview of 12 systematic reviews and 149 studies

Bellicha, A., van Baak, M. A., Battista, F., Beaulieu, K., Blundell, J. E., Busetto, L., Carraça, E. V., Dicker, D., Encantado, J., Ermolao, A., et al. (2021) · Obesity Reviews · doi:10.1111/obr.13256 · Cited by 375 · see citing works

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials

Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · see citing works

Diabetes Fact Sheet in Korea 2021

Bae, J. H., Han, K., Ko, S., Yang, Y., Choi, J. H., Choi, K. M., Kwon, H., & Won, K. C. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0106 · Cited by 361 · see citing works

Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials

He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, Y., Xu, L., Li, W., & Zhang, H. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0338 · Cited by 356 · see citing works

2020 Korean Society for the Study of Obesity Guidelines for the Management of Obesity in Korea

Kim, B.-Y., Kang, S. M., Kang, J., Kang, S. Y., Kim, K. K., Kim, K.-B., Kim, B., Kim, S. J., Kim, Y., Kim, J. H., et al. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21022 · Cited by 344 · see citing works

Executive summary: Guidelines (2013) for the management of overweight and obesity in adults

Members, E. P., Jensen, M. D., Ryan, D. H., Donato, K. A., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Hu, F. B., Hubbard, V. S., Jakicic, J. M., et al. (2014) · Obesity · doi:10.1002/oby.20821 · Cited by 337 · see citing works

Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis

Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304 · see citing works

Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US

Eberly, L. A., Yang, L., Essien, U. R., Eneanya, N. D., Julien, H. M., Luo, J., Nathan, A. S., Khatana, S. A. M., Dayoub, E. J., Fanaroff, A. C., et al. (2021) · JAMA Health Forum · doi:10.1001/jamahealthforum.2021.4182 · Cited by 288 · see citing works

Further purification of a polypeptide demonstrating enterogastrone activity

Brown, J. C., Mutt, V., & Pederson, R. A. (1970) · The Journal of Physiology · doi:10.1113/jphysiol.1970.sp009155 · Cited by 276 · see citing works

Recent updates on GLP-1 agonists: Current advancements & challenges

Sharma, D., Verma, S., Vaidya, S. P., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 272 · see citing works

Expert panel report: Guidelines (2013) for the management of overweight and obesity in adults

(2014) · Obesity · doi:10.1002/oby.20660 · Cited by 257 · see citing works

Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12D Mouse Model

Gier, B., Matveyenko, A. V., Kirakossian, D., Dawson, D., Dry, S. M., & Butler, P. C. (2012) · Diabetes · doi:10.2337/db11-1109 · Cited by 255 · see citing works

3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2023

ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D. M., et al. (2022) · Diabetes Care · doi:10.2337/dc23-s003 · Cited by 210 · see citing works

A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE -/- mouse model

Gaspari, T. A., Liu, H., Welungoda, I., Hu, Y., Widdop, R. E., Knudsen, L. B., Simpson, R. W., & Dear, A. E. (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111404257 · Cited by 203 · see citing works

Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism

Nyström, T., Gonon, A. T., Sjöholm, Å., & Pernow, J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.024 · Cited by 188 · see citing works

Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW)

Christensen, P., Meinert Larsen, T., Westerterp‐Plantenga, M., Macdonald, I., Martinez, J. A., Handjiev, S., Poppitt, S., Hansen, S., Ritz, C., Astrup, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13466 · Cited by 188 · see citing works

Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in <scp>J</scp>apanese patients (<scp>LEAN</scp>‐<scp>J</scp>)

Eguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182 · see citing works

Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression

Ishibashi, Y., Matsui, T., Takeuchi, M., & Yamagishi, S. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.075 · Cited by 173 · see citing works

The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension

Kim, H., Lee, E. M., Ahn, S. Y., Kim, K., Kim, H. C., Kim, J. H., Lee, H., Lee, J. H., Park, J., Cho, E. J., et al. (2023) · Clinical Hypertension · doi:10.1186/s40885-023-00234-9 · Cited by 167 · see citing works

GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity

Kadouh, H., Chedid, V., Halawi, H., Burton, D. D., Clark, M. M., Khemani, D., Vella, A., Acosta, A., & Camilleri, M. (2020) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/clinem/dgz140 · Cited by 166 · see citing works

Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension

Schutte, A. E., Jafar, T. H., Poulter, N. R., Damasceno, A., Khan, N. A., Nilsson, P. M., Alsaid, J., Neupane, D., Kario, K., Beheiry, H., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac130 · Cited by 164 · see citing works

Evaluation and Treatment of Obesity and Its Comorbidities: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity

Kim, K. K., Haam, J.-H., Kim, B. T., Kim, E. M., Park, J. H., Rhee, S. Y., Jeon, E. J., Kang, E., Nam, G. E., Koo, H. Y., et al. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23016 · Cited by 163 · see citing works

Glucagon-like peptide-1, glucose homeostasis and diabetes

Holst, J. J., Deacon, C. F., Vilsbøll, T., Krarup, T., & Madsbad, S. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.01.003 · Cited by 160 · see citing works

Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus

Ferdinand, K. C., White, W. B., Calhoun, D. A., Lonn, E., Sager, P. T., Brunelle, R. L., Jiang, H. H., Threlkeld, R. J., Robertson, K. E., & Geiger, M. J. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03062 · Cited by 146 · see citing works

Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight

Iurilli, M. L., Zhou, B., Bennett, J. E., Carrillo-Larco, R. M., Sophiea, M. K., Rodriguez‐Martinez, A., Bixby, H., Solomon, B. D., Taddei, C., Danaei, G., et al. (2021) · eLife · doi:10.7554/elife.60060 · Cited by 144 · see citing works

Hypertension prevalence and its trend in Bangladesh: evidence from a systematic review and meta-analysis

Chowdhury, M. Z. I., Rahman, M. M., Akter, T., Akhter, T., Ahmed, A., Shovon, M. A., Farhana, Z., Chowdhury, N. A., & Turin, T. C. (2020) · Clinical Hypertension · doi:10.1186/s40885-020-00143-1 · Cited by 143 · see citing works

Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis

Cameron-Vendrig, A., Adili, R., Siraj, M. A., Xu, X., Wang, Y., Lei, X., Afroze, T., Shikatani, E. A., El-Mounayri, O., Noyan, H., et al. (2016) · Diabetes · doi:10.2337/db15-1141 · Cited by 141 · see citing works

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial

Gerstein, H. C., Hart, R., Colhoun, H. M., Diaz, R., Lakshmanan, M., Botros, F. T., Probstfield, J., Riddle, M. C., Rydén, L., Atisso, C. M., et al. (2020) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(19)30423-1 · Cited by 137 · see citing works

Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes

Trujillo, J. M. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13225 · Cited by 131 · see citing works

Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes

Luna-Marco, C., de Marañon, A. M., Hermo-Argibay, A., Rodriguez-Hernandez, Y., Hermenejildo, J., Fernández-Reyes, M., Apostolova, N., Vila, J. M., Solá, E., Morillas, C., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102849 · Cited by 130 · see citing works

Renal effects of glucagon-like peptide in rats

Moreno, C., Mistry, M., & Roman, R. J. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01542-4 · Cited by 121 · see citing works

GLP1R Attenuates Sympathetic Response to High Glucose via Carotid Body Inhibition

Pauza, A. G., Thakkar, P., Tasic, T., Felippe, I., Bishop, P., Greenwood, M. P., Rysevaite-Kyguoliene, K., Ast, J., Broichhagen, J., Hodson, D. J., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.319874 · Cited by 106 · see citing works

Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice

Jojima, T., Uchida, K., Akimoto, K., Tomotsune, T., Yanagi, K., Iijima, T., Suzuki, K., Kasai, K., & Aso, Y. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.001 · Cited by 105 · see citing works

Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials

Fonseca, V. A., DeVries, J. H., Henry, R. R., Donsmark, M., Thomsen, H. F., & Plutzky, J. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.01.009 · Cited by 98 · see citing works

GLP-1 Agonists and Blood Pressure: A Review of the Evidence

Goud, A., Zhong, J., Peters, M. C., Brook, R. D., & Rajagopalan, S. (2016) · Current Hypertension Reports · doi:10.1007/s11906-015-0621-6 · Cited by 94 · see citing works

Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men

Asmar, A., Simonsen, L., Asmar, M., Madsbad, S., Holst, J. J., Frandsen, E., Moro, C., Jonassen, T. E. N., & Bülow, J. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00429.2014 · Cited by 93 · see citing works

Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6

Strain, W. D., Frenkel, O., James, M. A., Leiter, L. A., Rasmussen, S., Rothwell, P. M., Sejersten Ripa, M., Truelsen, T. C., & Husain, M. (2022) · Stroke · doi:10.1161/strokeaha.121.037775 · Cited by 93 · see citing works

GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells

Li, Q., Lin, Y., Wang, S., Zhang, L., & Guo, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-06712-z · Cited by 86 · see citing works

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies

Caruso, I., Cignarelli, A., Sorice, G. P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2022) · Metabolites · doi:10.3390/metabo12020183 · Cited by 86 · see citing works

Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States

Kim, N., Wang, J., Burudpakdee, C., Song, Y., Ramasamy, A., Xie, Y., Sun, R., Kumar, N., Wu, E. Q., & Sullivan, S. D. (2022) · Journal of Managed Care &amp; Specialty Pharmacy · doi:10.18553/jmcp.2022.28.7.740 · Cited by 81 · see citing works

GLP1 and cancer: friend or foe?

Vangoitsenhoven, R., Mathieu, C., & der Schueren, B. V. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0111 · Cited by 75 · see citing works

Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial

Anholm, C., Kumarathurai, P., Pedersen, L. R., Samkani, A., Walzem, R. L., Nielsen, O. W., Kristiansen, O. P., Fenger, M., Madsbad, S., Sajadieh, A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.07.007 · Cited by 75 · see citing works

Coverage for Obesity Prevention and Treatment Services: Analysis of Medicaid and State Employee Health Insurance Programs

Jannah, N., Hild, J., Gallagher, C., & Dietz, W. (2018) · Obesity · doi:10.1002/oby.22307 · Cited by 72 · see citing works

The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: a mini-review of the potential mechanisms

Ribeiro-Silva, J. C., Tavares, C. A. M., & Girardi, A. C. C. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2023.102355 · Cited by 71 · see citing works

Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis

† (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00240-0 · Cited by 70 · see citing works

20-Year Trends in Metabolic Syndrome Among Korean Adults From 2001 to 2020

Park, D., Shin, M., Després, J., Eckel, R. H., Tuomilehto, J. O., & Lim, S. K. (2023) · JACC Asia · doi:10.1016/j.jacasi.2023.02.007 · Cited by 62 · see citing works

Korea hypertension fact sheet 2022: analysis of nationwide population-based data with a special focus on hypertension in the elderly

Kim, H. C., Lee, H., Lee, H., Lee, G. B., Kim, E., Song, M., Moon, J., & Seo, Y. (2023) · Clinical Hypertension · doi:10.1186/s40885-023-00243-8 · Cited by 57 · see citing works

A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)

Nomoto, H., Miyoshi, H., Furumoto, T., Oba, K., Tsutsui, H., Miyoshi, A., Kondo, T., Tsuchida, K., Atsumi, T., Manda, N., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135854 · Cited by 52 · see citing works

Cost-effectiveness of endoscopic, surgical and pharmacological obesity therapies: a microsimulation and threshold analyses

Saumoy, M., Gandhi, D., Buller, S., Patel, S., Schneider, Y., Coté, G. A., Kochman, M. L., Thiruvengadam, N. R., & Sharaiha, R. Z. (2023) · Gut · doi:10.1136/gutjnl-2023-330437 · Cited by 52 · see citing works

Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis

Yeh, T., Tsai, M.-C., Tsai, W.-H., Tu, Y., & Chien, K. (2023) · PLoS ONE · doi:10.1371/journal.pone.0278685 · Cited by 51 · see citing works

The Role of Glucagon-Like Peptide-1 in Energy Homeostasis

Salehi, M., & Purnell, J. Q. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0088 · Cited by 49 · see citing works

Central Glucagon-like Peptide-1 Receptor Signaling via Brainstem Catecholamine Neurons Counteracts Hypertension in Spontaneously Hypertensive Rats

Katsurada, K., Nakata, M., Saito, T., Zhang, B., Maejima, Y., Nandi, S. S., Sharma, N. M., Patel, K. P., Kario, K., & Yada, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-49364-x · Cited by 46 · see citing works

Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta‐Analysis

Hu, M., Cai, X., Yang, W., Zhang, S., Nie, L., & Ji, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015323 · Cited by 46 · see citing works

Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting

Hu, Y., Zheng, S.-L., Ye, X.-L., Shi, J.-N., Zheng, X.-W., Pan, H.-S., Zhang, Y.-W., Yang, X.-L., & Huang, P. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-200 · Cited by 45 · see citing works

Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents

Lim, F., Bellows, B. K., Tan, S. X., Aziz, Z., Woo Baidal, J. A., Kelly, A. S., & Hur, C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.29178 · Cited by 42 · see citing works

GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Banerjee, M., Pal, R., Mukhopadhyay, S., & Nair, K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad076 · Cited by 41 · see citing works

Metabolomics profiling in hypertension and blood pressure regulation: a review

Onuh, J. O., & Aliani, M. (2020) · Clinical Hypertension · doi:10.1186/s40885-020-00157-9 · Cited by 40 · see citing works

Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight Benefits

Nauck, M. A., & Marre, M. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.1997 · Cited by 38 · see citing works

Modulatory role of gut microbiota in cholesterol and glucose metabolism: Potential implications for atherosclerotic cardiovascular disease

Roessler, J., Leistner, D. M., Landmesser, U., & Haghikia, A. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.08.018 · Cited by 37 · see citing works

Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective

Gómez-Lumbreras, A., Tan, M. S., Zapata, L. V., Ilham, S., Earl, J. C., & Malone, D. C. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.03.012 · Cited by 37 · see citing works

Obesity, hypertension, diabetes mellitus, and hypercholesterolemia in Korean adults before and during the COVID-19 pandemic: a special report of the 2020 Korea National Health and Nutrition Examination Survey

Lee, G. B., Kim, Y., Park, S., Kim, H. C., & Oh, K. (2022) · Epidemiology and Health · doi:10.4178/epih.e2022041 · Cited by 36 · see citing works

Trends in the prevalence and management of major metabolic risk factors for chronic disease over 20 years: findings from the 1998-2018 Korea National Health and Nutrition Examination Survey

Kim, Y., Nho, S. J., Woo, G.-J., Kim, H.-J., Park, S., Kim, Y., Park, O., & Oh, K. (2021) · Epidemiology and Health · doi:10.4178/epih.e2021028 · Cited by 35 · see citing works

Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management

Taha, M. B., Yahya, T., Satish, P., Laird, R., Agatston, A. S., Cainzos-Achirica, M., Patel, K. V., & Nasir, K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01041-7 · Cited by 31 · see citing works

Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-κB signalling pathway

Fan, S., Xiong, Q., Wang, L., Zhang, L., & Shi, Y. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111005 · Cited by 30 · see citing works

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: A Multisite Population-Based Cohort Study

Pradhan, R., Patorno, E., Tesfaye, H., Schneeweiß, S., Yin, H., Franklin, J. M., Pawar, A. M., Santella, C., Yu, O. H. Y., Renoux, C., et al. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac021 · Cited by 30 · see citing works

Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration

Woronow, D. I., Chamberlain, C. E., Niak, A., Avigan, M., Houstoun, M., & Kortepeter, C. M. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.3810 · Cited by 30 · see citing works

Current opinion on dietary advice in order to preserve fat-free mass during a low-calorie diet

Rondanelli, M., Faliva, M. A., Gasparri, C., Peroni, G., Spadaccini, D., Maugeri, R., Nichetti, M., Infantino, V., & Perna, S. (2020) · Nutrition · doi:10.1016/j.nut.2019.110667 · Cited by 29 · see citing works

Increased prevalence of metabolic syndrome among hypertensive population

Lee, S., Cha, M., Kang, D., Oh, K.-C., Shin, D., & Lee, H. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.11.095 · Cited by 28 · see citing works

Current Long-Term Pharmacotherapies for the Management of Obesity

Kim, B.-Y., Kang, S. M., Kang, J., Kim, K. K., Kim, B., Kim, S. J., Kim, Y., Kim, J. H., Kim, J. H., Nam, G. E., et al. (2020) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes20010 · Cited by 27 · see citing works

Resistant hypertension: consensus document from the Korean society of hypertension

Park, S., Shin, J., Ihm, S., Kim, K., Kim, H., Kim, H. C., Lee, E. M., Lee, J. H., Ahn, S. Y., Cho, E. J., et al. (2023) · Clinical Hypertension · doi:10.1186/s40885-023-00255-4 · Cited by 26 · see citing works

Obesity-related hypertension and chronic kidney disease: from evaluation to management

Jung, M., & Ihm, S. (2023) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.23.072 · Cited by 24 · see citing works

Effects of treatment with Glucagon‐like peptide‐1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta‐analysis

Wang, W., Wei, R., Huang, Z., Luo, J., Pan, Q., & Guo, L. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3680 · Cited by 22 · see citing works

Suboptimal control status of young hypertensive population

Shin, D., Choi, J., & Lee, H. (2023) · Clinical Hypertension · doi:10.1186/s40885-023-00237-6 · Cited by 22 · see citing works

Effect of carbohydrate-restricted diets and intermittent fasting on obesity, type 2 diabetes mellitus, and hypertension management: consensus statement of the Korean Society for the Study of obesity, Korean Diabetes Association, and Korean Society of Hypertension

Choi, J. H., Cho, Y. J., Kim, H., Ko, S., Chon, S., Kang, J., Kim, K. K., Kim, H. J., Kim, H. J., Song, K., et al. (2022) · Clinical Hypertension · doi:10.1186/s40885-022-00207-4 · Cited by 21 · see citing works

Addendum. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2023. Diabetes Care 2023;46(Suppl. 1):S41–S48

ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D. M., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-ad08a · Cited by 16 · see citing works

Molecular Processes Involved in the Shared Pathways between Cardiovascular Diseases and Diabetes

Tokarek, J., Budny, E., Saar, M., Stańczak, K., Wojtanowska, E., Młynarska, E., Rysz, J., & Franczyk, B. (2023) · Biomedicines · doi:10.3390/biomedicines11102611 · Cited by 12 · see citing works

Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes

Scalzo, R. L., Rafferty, D., Schauer, I. E., Huebschmann, A. G., Cree‐Green, M., Reusch, J. E. B., & Regensteiner, J. G. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.05.002 · Cited by 12 · see citing works

SELECTing Treatments for Cardiovascular Disease — Obesity in the Spotlight

Khera, A., & Powell‐Wiley, T. M. (2023) · New England Journal of Medicine · doi:10.1056/nejme2312646 · Cited by 12 · see citing works

Ideal cardiovascular health metrics and the risk of nonalcoholic fatty liver disease in Korean adults

Shim, S. Y., Jung, S. J., Kim, S. U., & Kim, H. C. (2023) · Clinical Hypertension · doi:10.1186/s40885-022-00227-0 · Cited by 10 · see citing works

Untitled work

Merchenthaler (1999) · doi:10.1002/(sici)1096-9861(19990111)403:2

GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity

Cooper, M. E., & van Raalte, D. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194749 · Cited by 24 · see citing works

Impact of Perioperative Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes Following Carpal Tunnel Release

Bank, N. C., Perle, S. J., Lauck, B. J., Rajesh, A. J., Jeffs, A. D., & Draeger, R. W. (2025) · Journal of Hand Surgery Global Online · doi:10.1016/j.jhsg.2025.100746 · Cited by 4 · see citing works

Nanotechnology-enabled targeted delivery of incretin therapies for the treatment of obesity and metabolic disorders

Uti, D. E., Egbung, J. E., Alum, E. U., Bawa, I., Agada, S. A., Ogbu, C. O., & Ugwu, O. P.-C. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100712 · Cited by 1 · see citing works

Long-Term Impact of New-Onset Diabetes Mellitus in Hypertensive Patients

Park, S., Kim, S., Shin, H. G., Park, K., Lee, S., Lee, H., Lee, J., Kim, K., Kang, S., Lee, J. H., et al. (2026) · Korean Circulation Journal · doi:10.4070/kcj.2026.0017 · Cited by 1 · see citing works

Cardiorenometabolic medicine as a new subspecialty in the light of novel pharmaceuticals with dual or triple benefits

Medenica, S., Prelević, V., Zanković, N., Maggio, V., & Rizzo, M. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2648248

Influence of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes

Matsushita, T., Wada, Y., Saburi, M., Kobayashi, K., Tsukamoto, S., Kawanami, D., Suzuki, D., Tsuriya, D., Wakui, H., Kanasaki, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-026-02695-5

Systemic pathways linking subcutaneous therapies to gastrointestinal adverse effects: A Narrative review of mechanisms and mitigation strategies

Singh, A. K., Yadav, D., & Singh, M. P. (2026) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_1343_25

Combination Therapy of GLP-1 RA and SGLT2i in Patients with Established Heart Failure: A Systematic Review and Meta-Analysis of Observational Studies

Tristan, C. D., Irnizarifka, I., Kynaya, E. M., Gani, M., Wijayanto, M. A., Asrial, A. A., & Pranata, R. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-026-00812-w

Hypertension as a Metabolic Disease: New-Onset Diabetes in the Korean Hypertension Cohort

Kim, H. (2026) · Korean Circulation Journal · doi:10.4070/kcj.2026.0358

Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome

Ravić, M. P., Srejovic, I. M., Andjic, M. M., Nikolić, M., Sretenovic, J. Z., Jeremic, N. S., Milosavljevic, I. M., Vuletić, M. L., Muric, N. N., Ravić, K. R., et al. (2026) · Medical Sciences · doi:10.3390/medsci14050590

Management of Hypertension, Obesity, Lipids, and Diabetes with Glucagon-like Peptide 1 Receptor Agonists

Chakravarti, H. N., Kesavadev, J., KOVIL, R. R., Sanyal, D., Das, S., Roy, N., Kumar, D., Deb, B., Chaudhuri, S. R., & Aneja, P. (2024) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_11_24 · Cited by 2 · see citing works

Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials

Wong, H. J., Toh, K. Z. X., Teo, Y. H., Teo, Y. N., Chan, M. Y., Yeo, L. L. L., Eng, P. C., Tan, B. Y., Zhou, X., Yang, Q., et al. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003903 · Cited by 26 · see citing works

GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review

Jarade, C., Zolotarova, T., Moiz, A., & Eisenberg, M. J. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102789 · Cited by 29 · see citing works

GLP-1-Rezeptor-Agonisten bei Bluthochdruck und Übergewicht

Babic, M., & van der Giet, M. (2025) · Die Nephrologie · doi:10.1007/s11560-025-00887-7

Beneficial effects of glucagon-like peptide-1 receptor agonists in overweight and obese patients

Αποστολίδης, Λ. Χ. (2024) · Aristotle University of Thessaloniki · doi:10.26262/heal.auth.ir.355788